open access
Angiopoietin-like proteins - their role in lipoprotein metabolism and association with atherogenic dyslipidemia
open access
Abstract
Scientists have been trying to find the best parameter for laboratory assessment of the risk of cardiovascular
diseases (CVD) for decades. Initially, the results of many studies indicated that the analysis
of the lipid profile was sufficient to evaluate the risk of CVD. Further studies revealed that more precise
laboratory prediction of cardiovascular risk requires quantification of atherogenic lipoproteins. Recently,
angiopoietin-like proteins 3, 4 and 8 (ANGPTLs) have been described as important regulators of plasma
lipoprotein metabolism and triglyceride homeostasis. Mutations in ANGPTL3 leading to loss of its function
have been linked to decreased risk of CVD in humans. Among potential new targets for the management
of dyslipidemia, ANGPTL3 may become a considerably promising one.
Abstract
Scientists have been trying to find the best parameter for laboratory assessment of the risk of cardiovascular
diseases (CVD) for decades. Initially, the results of many studies indicated that the analysis
of the lipid profile was sufficient to evaluate the risk of CVD. Further studies revealed that more precise
laboratory prediction of cardiovascular risk requires quantification of atherogenic lipoproteins. Recently,
angiopoietin-like proteins 3, 4 and 8 (ANGPTLs) have been described as important regulators of plasma
lipoprotein metabolism and triglyceride homeostasis. Mutations in ANGPTL3 leading to loss of its function
have been linked to decreased risk of CVD in humans. Among potential new targets for the management
of dyslipidemia, ANGPTL3 may become a considerably promising one.
Keywords
angiopoietin-like proteins, apolipoprotein B, cardiovascular disease, lipoprotein lipase, triglycerides
About this articleTitle
Angiopoietin-like proteins - their role in lipoprotein metabolism and association with atherogenic dyslipidemia
Journal
Issue
Article type
Review article
Pages
175-178
Published online
2018-11-02
Page views
927
Article views/downloads
784
DOI
Bibliographic record
Medical Research Journal 2018;3(3):175-178.
Keywords
angiopoietin-like proteins
apolipoprotein B
cardiovascular disease
lipoprotein lipase
triglycerides
Authors
Karolina Murawska
Łukasz Szternel
Grażyna Sypniewska
References (21)- Stanisławska J, Talarska D, Kudlińska A. Porównanie występowania czynników ryzyka choroby niedokrwiennej serca u chorych po przebytym zawale serca do osób bez klinicznych objawów tej choroby. Hygeia Public Health. 2014; 41: 127–133.
- Kappelle PJ, Gansevoort RT, Hillege JL, et al. PREVEND study group. Apolipoprotein B/A-I and total cholesterol/high-density lipoprotein cholesterol ratios both predict cardiovascular events in the general population independently of nonlipid risk factors, albuminuria and C-reactive protein. J Intern Med. 2011; 269(2): 232–242.
- Bilen O, Kamal A, Virani SS. Lipoprotein abnormalities in South Asians and its association with cardiovascular disease: Current state and future directions. World J Cardiol. 2016; 8(3): 247–257.
- Pencina MJ, D'Agostino RB, Zdrojewski T, et al. Apolipoprotein B improves risk assessment of future coronary heart disease in the Framingham Heart Study beyond LDL-C and non-HDL-C. Eur J Prev Cardiol. 2015; 22(10): 1321–1327.
- Keller T, Zeller T, Ojeda F, et al. Serial changes in highly sensitive troponin I assay and early diagnosis of myocardial infarction. JAMA. 2011; 306(24): 2684–2693.
- Walldius G, Jungner I, Holme I, et al. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. The Lancet. 2001; 358(9298): 2026–2033.
- Vakkilainen J, Mäkimattila S, Seppälä-Lindroos A, et al. Endothelial dysfunction in men with small LDL particles. Circulation. 2000; 102(7): 716–721.
- Muraba Y, Koga T, Shimomura Y, et al. The role of plasma lipoprotein lipase, hepatic lipase and GPIHBP1 in the metabolism of remnant lipoproteins and small dense LDL in patients with coronary artery disease. Clin Chim Acta. 2018; 476: 146–153.
- Wong H, Davis RC, Thuren T, et al. Lipoprotein lipase domain function. J Biol Chem. 1994; 269(14): 10319–10323.
- Dallinga-Thie GM, Kroon J, Borén J, et al. Triglyceride-Rich Lipoproteins and Remnants: Targets for Therapy? Curr Cardiol Rep. 2016; 18(7): 67.
- Kolovou GD, Kolovou V, Panagiotakos DB, et al. Study of common variants of the apolipoprotein E and lipoprotein lipase genes in patients with coronary heart disease and variable body mass index. Hormones (Athens). 2015; 14(3): 376–382.
- Xie Li, Li YM. Lipoprotein Lipase (LPL) Polymorphism and the Risk of Coronary Artery Disease: A Meta-Analysis. Int J Environ Res Public Health. 2017; 14(1).
- Santulli G. Angiopoietin-like proteins: a comprehensive look. Front Endocrinol (Lausanne). 2014; 5: 4.
- Cinkajzlová A, Mráz M, Lacinová Z, et al. Angiopoietin-like protein 3 and 4 in obesity, type 2 diabetes mellitus, and malnutrition: the effect of weight reduction and realimentation. Nutr Diabetes. 2018; 8(1): 21.
- Tikka A, Jauhiainen M. The role of ANGPTL3 in controlling lipoprotein metabolism. Endocrine. 2016; 52(2): 187–193.
- Morinaga J, Zhao J, Endo M, et al. Association of circulating ANGPTL 3, 4, and 8 levels with medical status in a population undergoing routine medical checkups: A cross-sectional study. PLoS One. 2018; 13(3): e0193731.
- Dewey FE, Gusarova V, O'Dushlaine C, et al. Inactivating Variants in ANGPTL4 and Risk of Coronary Artery Disease. N Engl J Med. 2016; 374(12): 1123–1133.
- Dijk W, Beigneux AP, Larsson M, et al. Angiopoietin-like 4 promotes intracellular degradation of lipoprotein lipase in adipocytes. J Lipid Res. 2016; 57(9): 1670–1683.
- Abid K, Trimeche T, Mili D, et al. ANGPTL4 variants E40K and T266M are associated with lower fasting triglyceride levels and predicts cardiovascular disease risk in Type 2 diabetic Tunisian population. Lipids Health Dis. 2016; 15: 63.
- Coding Variation in ANGPTL4, LPL, and SVEP1 and the Risk of Coronary Disease. New England Journal of Medicine. 2016; 374(19): 1898–1898.
- Drenos F, Davey Smith G, Ala-Korpela M, et al. Metabolic Characterization of a Rare Genetic Variation Within APOC3 and Its Lipoprotein Lipase-Independent Effects. Circ Cardiovasc Genet. 2016; 9(3): 231–239.